Berenice Gitomer, PhD

Reed BY, McFann K, Bekheirnia MR, Nobkhthaghighi N, Masoumi A, Johnson AM, Shamshiraz AA, Kelleher CL, Schrier RW. Variation in age at ESRD in autosomal dominant polycystic kidney disease. Am J Kid Dis. 51: 173-182, 2008

Polymorphisms in the IL 8 and ANGPT2 genes are associated with increased risk for liver cystic disease in ADPKD. Reed-Gitomer BY, McFann K, Masoumi A, Amura C, Doctor B, Yan X-D, Christopher K, Petersen E, Kelleher C, Schrier RW. J Am Soc Nephrology 18: 366A, 2007

Amura C, Brodsky KS, Gitomer B, McFann K, Lazennec G, Nichols MT, Jani A, Schrier RW, Doctor RB. CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiology In Press 2008.

Masoumi A, Reed-Gitomer B, Kelleher C, Reza MR, Schrier RW. Developments in the management of autosomal dominant polycystic kidney disease. In Therapeutics and Clinical Risk Management 4: pp 1-15, 2008 Dove Medical press.

Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW. Potential pharmacological interventions in polycystic kidney disease. Drugs 67: 2495-2510, 2007

Reed B, McFann K, Kimberling WJ, Pei Y, Gabow PA, Christopher K, Petersen E, Kelleher C, Pain PR, Johnson A, Schrier RW. Presence of De Novo Mutations in Autosomal Dominant Polycystic Kidney Disease Patients Without Family History. Am J Kidney Dis. 52:1042-1050

Circulating Angiopoietin Level is Correlated with Renal Cyst Number in Young ADPKD Patients. Elhassan E, Masoumi A, Cadnapaphornchai M, Yan X-D, Gitomer S, Reed-Gitomer B, Schrier RW. J Am Soc Nephrol. 19:126A

A Genome-Wide Search for Modifier Genes in PKD1. Gitomer B, Gowan K, McFann KK, Yan X-D, Schrier RW, Fain PR. Submitted Am J Med Gen. 2009

Reed-Gitomer BY, Bekheirnia MR, Wang W,Masoumi A, Gianani R, Wong R, Schrier RW. Angiogenesis and autosomal dominat polycystic kidney disease.J Am Soc Nephrol. 20:276A, 2009

Masoumi A, Bekheirnia MR, Reed-Gitomer BY, Gregory MC, McFann K, Shamshirsaz AA, Schrier RW. X-linked Alport syndrome: Study of genotype-phenotype correlation in a male US population. J Am Soc Nephrol. 20:773A,2009

Nobakht E, Dadgar S, Bekheirnia MR, Masoumi A, Belibi F, Yan X-D, Cadnapaphornchai M, Reed-Gitomer B, Schrier RW. Renal ultrasonographic diagnosis of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol. 20:498A,2009

Reed-Gitomer BY, Wang W, Masoumi A, Cadnapaphornchai M, Schrier RW. Angiogenesis and autosomal dominant polycystic kidney disease. Proc. Butcher Symposium on Genomics and Technology 88, 2009.

Reed B,Nobakht E, Dadgar S, Bekheirnia MR, Masoumi A, Belibi F, Yan X-D, Cadnapaphornchai M, Schrier RW. Renal ultrasonographic evaluation in children at risk for polycystic kidney disease. Am J Kid Dis. Accepted pending revision review 2010

Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW.Genotype/phenotype correlation in American men with Alport syndrome. Accepted pending revision review J Am Soc Nephrol. In review 2010

Reed B, Masoumi A, Elhassan E, Wang W, Mc Fann K, Cadnapaphornchai M, Schrier RW. Angiogenic growth factors in young patients with autosomal dominant polycystic kidney disease. Kid. Int. Revision under review. 2010

Liu M, Shi S, Senthilnathan S, Yu J, Wu E, Bergmann C, Bogdanova N, Coto E, Deltas CC, Devuyst O, Reed-Gitomer B, Laakso M, Lamnisou K, Magistroni R, Palfrey P, Breuning M, Peters D, Torra R, Winearls C, Torres V, Harris P, Paterson AD, Pei Y. Genetic modifiers of renal disease severity in PKD1. J Am Soc Nephrol. submitted 2010

Reed B,Nobakht E, Dadgar S, Bekheirnia MR, Masoumi A, Belibi F, Yan XD, Cadnapaphornchai M, Schrier RW. Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010 56;50-56.

Reed BY, Masoumi A, Elhassan E, McFann K, Cadnapaphornchai M, Maahs DM, Snell-Bergeon JK, Schrier RW. Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011:79:128-134

Liu M, Shi S, Senthilnathan S, Yu J, Wu E, Bergmann C, Zerres K, Bogdanova N, Coto E, Deltas C, Pierides A, Demetriou K, Devuyst O, Gitomer B, Laakso M, Lumiaho A, Lamnissou K, Magistroni R, Parfrey P, Breuning M, Peters DJ, Torra R, Winearls CG, Torres VE, Harris PC, Paterson AD, Pei Y. Genetic variation of DKK3 may modify renal disease severity in ADPKD. J Am Soc Nephrol. 2010;21:1510-1520

Schrier RW, Wang W, Chonchol M, Cadapaphornchai M, McFann K, Yan X-D, Gitomer B.Klotho expression is reduced in human kidneys from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2010;21:887A

Gitomer BY, Cadnapaphornchai M, Masoumi A, Chonchol M, McFann K, Wang Wei, Yan X-D, Schrier RW. Vitamin D deficiency and renal volume in autosomal dominant polycystic kidney disease.J Am Soc Nephrol. 2010;529A.

Gitomer BY, Cadnapaphornchai M, Wang W, Masoumi A, McFann K, Yan X-D, Schrier RW. Vascular endothelial growth factor level correlates with disease severity in young patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2010; 21:526A-527A

Wang W, Gitomer BY, McFann K, Yan X-D, Schrier RW. Type II diabetes in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2010; 21:889A

Masoumi A, Gitomer BY, Schrier RW, Wang W, Chapman AB, Perrone RD, Torres VE, Steinman TI, Miskulin DC. Effect of angiotensin converting enzyme (ACE) inhibition and angiotensin receptor blockade on urinary pH in ADPKD. J Am Soc Nephrol. 2010;21:532A

Cadnapaphornchai MA, Gitomer BY, Chonchol MB, McFann K, Wang W, Schrier RW. Prevalence of vitamin D deficiency in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2010;21:882A

Helal I, Reed B, McFann K, Yan X-D, Schrier R. Renal hyperfiltration relationship with renal volume in early stages of autosomal dominant polycystic kidney disease. Proc. ISN 2011 in press

Reed B, Helal I, McFann K, Wang W, Yan XD, Schrier RW. The impact of type II diabetes mellitus in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. Dec 29, 2011 epub ahead of print

Brosnahan GM, Helal I, Reed BY. Alport Syndrome, Fabry Disease, and Nail Patella Syndrome. In: Diseases of the kideny and urinary tract (9th edition)RW Schrier Ed., Lippincott, Williams, Wilkins, Philadelphia PA, 2012 In press

Reed BY, Wang W. Angiogenesis and the pathogenesis of autosomal dominant polycystic kidney disease. In: Nephrology, Intech,Rijeka, Croatia 2012 In press

Helal I, Reed B, McFann K, Yan X-D, Fick-Brosnahan G, Cadnapaphornchai M, Schrier RW. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.Clin J Am Soc Nephrol. 6:2439-2443, 2011

Helal I, Fick-Brosnahan G, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration:definitions, mechanisms, and clinical implications. Nature Rev Nephrology 2012 In Press

Gitomer BY, McFann K, Wolf MS, Schrier RW, Chonchol M. Fractional excretion of phosphate is independently associated with renal volume and left ventricular mass index in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 22: 300A, 2011

Wang W, Schrier RW, Gitomer BY. MicroRNA regulation of angiogenesis in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 22:577A

Klawitter J, Klawitter J, Corby K, Christians U, Schrier RW, Chonchol MB, Gitomer BY. Methylation cycle intermediates in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 22: 299A

Klawitter J, Klawitter J, Corby K, Christians U, Schrier RW, Gitomer BY, Chonchol MB. Biomarkers of endothelial dysfunction and vascular inflammation in ADPKD. J Am Soc Nephrol 22: 299A

Jovanovich AJ, Gitomer BY, Wolf MS, Yan X-D, Schrier RW, Chonchol MB. Renal phosphate leak in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 22:299A

Sharma S, Chonchol MB, Gitomer BY, Wang W, Wolf MS, Cadnapaphornchai M, Schrier RW. Fibroblast growth factor 23 levels are elevated in children and adults with autosomal dominant polycystic kidney disease and preserved renal function. J Am Soc Nephrol 22: 297A

Helal I, Gitomer BY, Yan X-D, McFann K, Brosnahan GM, Schrier RW. Changing demographics of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 22: 901A

Helal I, Gitomer BY, McFann K, Yan X-D, Brosnahan GM, Schrier RW. Serum uric acid and renal disease progression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 22:300A

Reed-Gitomer BY, Wang W, McFann K, Cadnaphornchai M, Schrier RW, Chonchol M.Vitamin D and severity of autosomal dominant polycystic kidney disease. In: Polycystic kidney disease from bench to bedside, Proceedings of the FASEB Summer research Conference 2011

The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Reed B, Helal I, McFann K, Wang W, Yan XD, Schrier RW. Nephrol Dial Transplant. 2012 Jul;27(7):2862-5. doi: 10.1093/ndt/gfr744. Epub 2011 Dec 29. PMID:22207329

Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Helal I, Reed B, Schrier RW. Am J Nephrol. 2012;36(2):162-7. doi: 10.1159/000341263. Epub 2012 Jul 26. Review. PMID:22846584

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Nephrol Dial Transplant. 2013 Feb;28(2):380-5. doi: 10.1093/ndt/gfs417. Epub 2012 Dec 4. PMID:23222419

Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Helal I, Reed B, Mettler P, Mc Fann K, Tkachenko O, Yan XD, Schrier RW. Am J Nephrol. 2012;36(4):362-70. doi: 10.1159/000343281. Epub 2012 Oct 4. PMID:23038404

Current standard of care for autosomal dominant polycystic kidney disease patients. Reed-Gitomer BY. Perrone R. FDA Briefing Book for PKD Outcomes Consortium 2012

Autosomal dominant polycystic kidney disease: cardiovascular complications. Reed-Gitomer BY. Current Hypertension Reviews: Autosomal Dominant Polycystic Kidney Disease. Ed. Reed-Gitomer BY. Publ: Bentham Science. In Press Feb. 2013

Wang W , Chonchol MB, Schrier RW, Gitomer BY. Aberrant VEGF and sFlt-1 expression in ADPKD patients. J Am Soc Nephrol. 2012 23: 703A

Wang W , Chonchol MB, Schrier RW, Gitomer BY. Differential Renal Gene Expression in ADPKD Compared to Other CKD Causes. J Am Soc Nephrol. 2012 23: 949A

Wang W , Chonchol MB, Schrier RW, Gitomer BY A Functional Variant of Angiopoietin-1 is Associated with Hypertension and Severity of Renal Structural Damage in Patients with ADPKD J Am Soc Nephrol. 2012 23: 702A

Gitomer BY, McFann K, Yan X-D, Wang W, Helal I, Brosnahan GM, Schrier RW. Affected Parent Gender and Severity of ADPKD. J Am Soc Nephrol. 2012 23: 704A

Gitomer BY, Jablonski KL, Tan AC,Wang W, Lader E, Shaffer JM, Chonchol MB. Micro RNA Profile Distinguishes Subjects with Cardiovascular Risk Factors from Healthy Individuals. J Am Soc Nephrol. 2012 23: 1001A

Gitomer BY, Edelstein CL, Wang W, Lader E, Shaffer JM, Chonchol MB. Circulating Micro-RNAs in Acute Kidney Injury after Liver Transplantation: early observations. J Am Soc Nephrol. 2012 23: 376A

Endothelial dysfunction and vascular inflammation in ADPKD Klawitter J, Klepacki J, Pennington AT, Klawitter J, Schrier RW, Chonchol MB, Gitomer BY, Christians U. J Am Soc Nephrol. 2012 23: 703A

Helal I, Gitomer BY, Mettler P, McFann K, Tkachenko O, Yan X-D, Schrier RW. Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2012 23: 702A

Helal I, Gitomer BY, Mettler P, McFann K, Tkachenko O, Yan X-D, Schrier RW. Changing pattern of end-stage kidney disease in autosomal dominant polycystic kidney disease patients over time. J Am Soc Nephrol. 2012 23: 702A

FDA Briefing Book for PKD Outcomes Consortium 2013. Reed-Gitomer BY, Perrone R.FDA Briefing book for PKD outcomes consortium FDA submission May 2013.

Klawitter J, Zafar I, Klawitter J, Pennington AT, Klepacki J, Gitomer BY, Schrier RW, Christians U, Edelstein CL. Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD Rat model of polycystic kidney disease. BMC Nephrol. 2013 Jul 31;14(1):165. [Epub ahead of print] PubMed PMID: 23902712

Helal I, McFann K, Reed B, Yan XD, Schrier RW. Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med. 2013 Sep;126(9):832.e7-832.e11. PubMed PMID: 23830538

Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013 Feb;28(2):380-5. PubMed PMID: 23222419

Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai M, Chonchol M, Gitomer B, Christians U, Schrier RW. Bioactive lipid mediatorsin polycystic kidney disease.J Lipid Res. 2013 Dec. 16 Epub ahead of print

Reed-Gitomer B. Autosomal dominant polycystic kidney disease: cardiovascular complications. Curr Hypertens Rev. 2013 Feb;9(1):1. PubMed PMID: 23971637

Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW. Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1198-206. PubMed PMID: 25234311

Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014 Nov;25(11):2399-418. PubMed PMID: 24925719

Guay-Woodford LM, Henske E, Igarashi P, Perrone RD, Reed-Gitomer B, Somlo S, Torres VE, Ketchum CJ, Star RA, Flessner MF, Rasooly RS. Filling the holes in cystic kidney disease research. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1799-801. PubMed PMID: 24903391

Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 May;9(5):889-96. PubMed PMID: 24721893

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB, HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11;371(24):2255-66. PubMed PMID: 25399733

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD, HALT-PKD Trial Investigators. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11;371(24):2267-76. PubMed PMID: 25399731

Reed-Gitomer B. Autosomal dominant polycystic kidney disease:genetics,epidemiology and treatment. Adv. Gen. and Genomics. 2014. 4, 173-183

RD Perrone, JF Marier, MS Mouksassi, F Czerwiec, K Romero, E Dennis, D Miskulin, A Chapman, B Gitomer, and VE Torres for the PKD Outcomes Consortium. Qualification of total kidney volume as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease. (2014) National Kidney Foundation

Reed-Gitomer B. Vitamin D deficiency: a nontraditional risk factor in polycystic kidney disease?. Am J Physiol Renal Physiol. 2013 Oct 1;305(7):F975-6. PubMed PMID: 23804446

Wang W, Cadnapaphornchai MA, Chonchol M, Schrier RW, Gitomer BY. Pravasatatin and angiogenesis in ADPKD. J Am Soc Nephrol. 2013 24: 690A

Wang W, Chonchol M, Brosnahan GM, Schrier RW, Gitomer BY. Thrombospondin and autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2013 24:690A

Marier JF, Gosselin NH, Chittenden JT, Czerwiec FS, Levy DI, Chapman AB, Gitomer BY, Torres VE, Dennis EH, Romero K, Miskulin D, Perrone RD. Total kidney volume is a prognostic biomarker for worsening of kidney function in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2013 24: 686A

Marier JF, Moukassi M-S, Jonsson F, Czerwiec FS, Levy DI, Chapman AB, Gitomer BY, Torres VE, Dennis EH, Romero K, Miskulin D, Perrone RD. Total kidney volume is a prognostic indicator for progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease over 10-years. J Am Soc Nephrol. 2013 24: 686A

Gitomer BY, Pereira RC, Malaczewski MR, Wolf MS, Salusky I B, Stoneback JW, Chonchol M. Identification of a bone defect in ADPKD. J Am Soc Nephrol. 2014 25, 655A

Wang W, Gitomer B, Jablonski K, Schrier RW, Chonchol M. MitoQ modulates hypoxia-inducible factor-1a in ADPKD cells. J Am Soc Nephrol. 2014 25, 412A

Wang W, Cadnapaphornchai M, Chonchol M, Brosnahan G, Schrier RW, Gitomer B. Statin effect of human ADPKD tubular epithelial cell proliferation. J Am Soc Nephrol. 2014 25, 412A

Perrone RD, Broadbent S, Rome L, Chapman AB, Gitomer BY, Torres VE, Romero K, LeRoy B, Neville J, Lundstrom G, Marier JF, Czerwiec FS, Ostroff C, Drake M, Levy DI, Neylan J, Stafford B, Kopko S, Miskulin D. Qualification of Total Kidney Volume as a Prognostic Biomarker for use in Clinical Trials Evaluating Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Briefing Book for FDA and EMA. In Press 2013

Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA. Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1534-41. PubMed PMID: 26224879

Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, Czerwiec FS, Dennis E, Kisler B, Kopko S, Krasa HB, LeRoy E, Castedo J, Schrier RW, Broadbent S. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct;66(4):583-90. PubMed PMID: 26088508

Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul;88(1):17-27. PubMed PMID: 25786098

Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. In Press 2015

Fick-Brosnahan B, Reed BY. Diagnositic and prognostic biomarkers in autosomal dominant polycytic kidney disease. In Biomarkers of Kidney Disease 2nd Edition. Ed. Edelstein CL. Publ. Elsevier, San Diego CA. In press 2015

Wang W, Chonchol M, Gitomer BY. Aberrant expression of Rad9 in ADPKD. J Am Soc Nephrol. 26; 132A, 2015

Wang W, Chonchol M, Cadnapaphornchai MA, Gitomer BY. Effect of simvastatin on cell adhesion in ADPKD. J Am Soc Nephrol. 26; 132A, 2015

Pereira RC, Gitomer BY, Salusky IB, George D, Stoneback JW, King KB, Wolf MS, Chonchol M. Fourier transform infrared spectroscopy crystallinity indices in bone from patients with ADPKD. J Am Soc Nephrol. 26; 753A, 2015

Chonchol M, Gitomer BY, Cai X, Isakova T, Salusky IB, Pereira RC, Wolf MS. Fibroblast growth factor 23, renal progression and death in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 26; 832A, 2015

Brosnahan GM, Chonchol M, Holmen JR, Nuccio EJ, Gitomer B. Effect of metformin on the progression of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 26; 833A, 2015

Czerwiec FS, Blais J, Marier JF, Gosselin NH, Peyret T, Torres VE, Chapman AB, Gitomer BY, Broadbent ST, Miskulin D, Perrone RD. Adapted PKDOC disease predicts actual progression of autosomal dominant polycystic kidney disease in TEMPO3:. J Am Soc Nephrol. 26;827A, 2015

Brody JS, Wang W, Schrier RW, Reed-Gitomer B. Effects of smoking on ADPKD: Frequency of vascular events and concentration of soluble CD40 ligand. Gen Med. 3. 175, 2015.

Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2016;44(3):171-8. PubMed PMID: 27548646

Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016 Mar 21. [Epub ahead of print] PubMed PMID: 27001648

Perrone RD, Mouksassi M-S, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. Total kidney volume is a prognostic biomarker of renal function worsening and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kid. Int. 2016 Jan 09 In Press.

Wang W, Cadnapaphornchai M, Chonchol M, Gitomer B. Angiogenic factors predict progression in young patients with autosomal dominant polycystic kidney disease. EC Pediatrics. 2016 2.4: 205-214.

Fick-Brosnahan GM, Reed BY. Diagnostic and prognostic biomarkers in autosomal dominant polycystic kidney disease. In Biomarkers of Kidney Disease 2nd edition. 2016 Ed. C. Edelstein. Elsevier, Academic press. pp 513-530

Wang W, Chonchol M, Gitomer BY. Fibrosis markers in autosomal dominant polycystic kidney disease. J. Am Soc Nephrol. 2016 27: 764A

Gitomer BY, Stoneback JW, Pereira RC, Salusky IB, George D, Wang W, Wolf MS, Chonchol M. Bone mineral density is reduced in patients with autosomal dominant polycystic kidney disease. 2106. J Am Soc Nephrol. 27:770A

Gitomer BY, Wolf MS, Salusky IB, You Z, Chonchol M. Low serum levels of alkaline phosphatase are associated with greater total kidney volume in patients with early autosomal dominant polycystic kidney disease.2016 J Am Soc Nephrol.27:854A.

Nowak KL, You Z, Wolf MS, Chonchol M, Gitomer BY. Low levels of 1,25-dihydroxyvitamin D, not 25-hydroxyvitamin D are associated with greater total kidney volume (TKV) in patients with early autosomal dominant polycystic kidney disease. 2016 J Am Soc Nephrol. 27:961A

Nowak KL, You Z, Gitomer BY, Chonchol M, Cadnapaphornchai MA. Serum bicarbonate levels and total kidney volume in children and young adults with autosomal dominant polycystic kidney disease. 2016. J Am Soc Nephrol. 27:769A.

Brosnahan GM, Gitomer BY, Wang W, You Z, Nowak KL, Jalal DI, Chonchol M. Serum uric acid, total kidney volume and disease progression in autosomal dominant polycystic kidney disease: results from the HALT PKD trial. 2016 J Am Soc Nephrol. 27:769-770A

Cornec-Le Gall E, Gitomer BY, Chapman AB, Yu ASL, Peters DJM, Blumenfeld JD, Pei YP, Bae KT, Rubio D, Heyer CM, Mauritz SR, Torres VE, Harris PC. Determinants of disease variability in ADPKD: Insights from a cohort of 1634 PKD1 patients. 2016 J AmSoc Nephrol. 27:766A.

Jovanovich AJ, You Z, Gitomer BY, Wolf MS, Chonchol M. Fibroblast growth factor 23 is not associated with incident acute kidney injury among HALT study B participants. 2106. J Am Soc Nephrol. 27:220A.

Chonchol M, Gitomer By, You Z, Wolf MS. High serum levels of fibroblast growth factor 23 are associated with decreased renal blood flow in early autosomal dominant polycystic kidney disease. 2016. J Am Soc Nephrol. 27:218A.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017 May;2(3):451-460. PubMed PMID: 29142972

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017 May;2(3):442-450. PubMed PMID: 29142971

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2017 Nov 8. [Epub ahead of print] PubMed PMID: 29118087

Nowak KL, Chonchol M, You Z, Gupta M, Gitomer B. Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study?. Clin Nephrol. 2017 Oct 16. [Epub ahead of print] PubMed PMID: 29035198

Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1461-1469. PubMed PMID: 28705885

Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Feb 1;32(2):342-347. PubMed PMID: 28186577

Kleczko EK, Marsh KH, Clambey ET, Furgeson SB, Gitomer BY, Chonchol M, Nemenoff RA, Hopp K.Activation of CD8+ T-cells inhibits cyst growth in a murine model of ADPKD. J Am Soc Nephrol. 2017; 28. 247

Nowak KL, Gitomer BY, Farmer-Bailey H, Wang W, George D, Malaczewski MR, Chonchol M. Mineralocorticoid antagonism and vascular function in early autosomal dominant polycystic kidney disease: A randomized controlled trial. J Am Soc Nephrol. 2017;28.479

Gitomer BY, Wang W, Nowak KL, Hopp K, You Z, Brosnahan GM, Harris PC, Torres VE, Chapman AB, Perrone RD, Steinman TI, Yu AS, Abebe KZ, Bae KT, Chonchol M. Circulating interleukin-6 level predicts decline in kidney function in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2017;28.481

Nowak KL, Wang W, Gitomer BY, Jovanovich AJ, Farmer-Bailey H, Chonchol M. Mineralocorticoid antagonism vascular oxidative stress and inflammation in early autosomal dominant polycystic kidney disease. 2017;28.451

Nowak KL, You Z, Gitomer BY, Brosnahan GM, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoiu FF, Yu AS, Harris PC, Bae KT, Chonchol M. overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. 2017;28.1063

Gitomer BY, Dalyrmple LS, You Z, Ofshun NJ, Maddux FW, Isakova T, Salusky IB, Wolf MS, Chonchol M. Fracture rates and post-discharge outcomes among patients undergoing hemodialysis accross etiologies of kidney diseases. 2017;28.302

Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8( ) T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018 Dec;94(6):1127-1140. PubMed PMID: 30249452

Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1493-1501. PubMed PMID: 30228110

Nowak KL, Chonchol M, You Z, Gupta M, Gitomer B. Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study?. Clin Nephrol. 2018 Mar;89(3):196-204. PubMed PMID: 29035198

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 Feb;29(2):571-578. PubMed PMID: 29118087

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT PKD trial Investigators. Patterns of kidney function decline in autosomal domiant polycystic kidney disease: A post-hoc analysis from the HALT-PKD trials. Am J Kidney Dis.2018 May, 8 (13):666-676. pubMed PMID30228110.

Semplo C, Klawitter J, Christians U, Chonchol M, Cadnapaphornchai MA, Gitomer BY, Klawitter J.Assessment of endocannabinoid system as a biomarker for progression of ADPKD.J Am Soc Nephrol. 2018 29; 869.

Noureddine LA, Gitomer BY, You Z, Wang W, Chonchol M, Jalal DI, HALT Investigators. Exploring Kim-1 as a marker for kidney disease in ADPKD: Analysis from the HALT-PKD studies. J Am Soc Nephrol. 2018. 29; 869.

Baliga M, Klawitter J, Christians U, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J. Identifying urine biomarkers of disease progression in autosomal dominant polycystic kidney disease patients. J Am Soc Nephrol..2018. 29;868.

Baliga M, Klawitter J, Christians U, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J. Plasma metabolomics to identify biomarkers and altered pathways in ADPKD.J Am Soc Nephrol. 2018. 29;868.

Nowak KL, Malaczewski MR, Gitomer BY, George D, Chonchol M. Arterial stiffness is independently associated with total kidney volume in children and young adults with ADPKD. J Am Soc Nephrol. 2018. 29;867

Nowak KL, Malaczewski MR, Gitomer BY, George D, Chonchol M. Overweight and obesity are independently associated with total kidney volume in children and young adults with ADPKD J Am Soc Nephrol. 2018. 29;867

Gitomer BY, You Z, Wang W, Brosnahan GM, Nowak KL, Hopp K, Harris PC, Torres VE, Chapman AB, Perrone RD, Steinman TI, Yu AS, Bae KT, Abebe K, Chonchol M. Nephrolithiasis as a risk factor for kidney disease progression in ADPKD. J Am Soc Nephrol. 2018.29;867

Gitomer BY, Wang W, Tan AC, You Z, Nowak KL, Hopp K, Brosnahan GM,Harris PC, Torres VE, Chapman AB, Perrone RD, Steinman TI, Yu AS, Bae KT, Abebe K, Chonchol M. Serum micro RNA levels and disease progression in ADPKD. J Am Soc Nephrol. .2018.29;867

Yapa R, You Z, Gitomer BY, Chonchol M, Kendrick JB. Association of serum bicarbonate levels with kidney function decline in patients with polycystic kidney disease. J Am Soc Nephrol.2018. 29;472

Patel N, Gitomer BY, George D, Nowak KL, Chonchol M. Stiffeness imaging in native kidneys by magnetic resonance elastography: A feasibility study. J Am Soc Nephrol. 2018. 29;313

Hanudel MR, Salusky IB, Pereira RC, Wang W, You Z, Gitomer BY, Nowak KL, Chonchol M. FGF23, erythropoietin and erythroferrone levels in autosomal dominant polycystic kidney disease patients. J Am Soc Nephrol. 2018. 29;161

Grau LK, Gitomer BY, Chonchol M, Wolf M, Harris PC, Brosnahan GM, Torres VE, Steinman TI, Yu AS, Chapman AB, Nowak KL. Interactions between FGF23 and genotype in autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2018. 29;160.

Kendrick JB, You Z, Gitomer BY, Chonchol M,Blaine J. Association of serum bicarbonate levels with serum fibroblast growth factor-23 levels. J Am Soc Nephrol. 2018. 29;160

Jovanovich AJ, You Z, Gitomer BY, Wolf M, Salusky IB, Chonchol M, Nowak KL. Fibroblast growth factor 23 (FGF23) and cystic liver disease in patients with autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2018. 29;158

Tyler LC, Kleczko EK, Marsh KH, Wallace DP, Chonchol M, Gitomer BY, Nemenoff RA, Hopp K. CD8+ T-cells regulate progression of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018. 29;30

Nowak KL, Gitomer B, Farmer-Bailey H, Wang W, Malaczewski M, Klawitter J, You Z, George D, Patel N, Jovanovich A, Chonchol M. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. Am J Kidney Dis. 2019 Aug;74(2):213-223. PubMed PMID: 30803706

Hopp K, Cornec-Le-Gall E, Senum SR, te Paske I, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Cahapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui F, Torres VE, The HALT Progression of Polycystic Kidney Disease Group, The Modifier Study, Harris PC. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. epub ahead of print October 9, 2019.

Schafer M, Bjornstad P, Bispham N, You Z, Nowak KL, Hopp K, Brosnahan GM, Chonchol M, Gitomer BY. Peak renal blood flow rate correlates with renal function in adults with ADPKD. J Am Soc Nephrol. 2019, 30: 341.

Gitomer BY, Pereira RC, Salusky IB, Wang W, Hopp K, Jovanovich AJ, You Z, Nowak KL, Chonchol M. The affect of PKD gene mutation on bone. J Am Soc Nephrol. 2019, 30:252.

Ramirez-Renteria L, You Z, Gitomer BY, Chonchol M, Kendrick JB. Serum bicarbonate levels are not associated with total kidney volume in patients with polycystic kidney disease. J Am Soc Nephrol. 2019, 30:513.

Joli G, Senum SR, Raj S, Te Paske IB, Cornec-Le-Gall E, Lavu S, Coto E, Gitomer BY, Steinman TI, Torres VE, Harris PC. Characterization of ADPKD-like patients monallelic for ALG8. J Am Soc Nephrol. 2019, 30:624.

Wang W, Klawitter J, You Z, Nowak KL, Hopp K, Brosnahan GM, Chonchol M, Gitomer BY. Global DNA hypomethylation in autosomal domiant polycystic kidney disease. J Am Soc Nephrol. 2019, 30:632.

Nguyen D, Kleczko EK, Gitomer BY, Clambey ET, Chonchol M, Klawitter J, Nemenoff RA, Hopp K. Targeting immunosuppressive pathways reduces ADPKD progression in a relevant mouse model. J Am Soc Nephrol. 2019, 30:882.

Patel N, Gitomer BY, Nowak KL, Chonchol M. Stiffness imaging in native kidneys by magnetic resonance elastography: A feasibility study. Proceedings of the Consortium for Fibrosis Research and Translation Fall Symposium. 2019.

Steele C, You Z, Gitomer BY, Brosnahan GM, Harris PC, Torres VE, Abebe KZ, Steinman TI, Yu AS, Perrone RD, Braun WE, Chapman AB, Chonchol M,Nowak KL. PKD1 compared with PKD2 genotype and cardiac hospitalizations in the HALT-PKD studies. J Am Soc Nephrol. 2020; 31: 488

Wang W, You Z, Gitomer BY, Brosnahan GM, Harris PC, Miskulin D, Torres VE, Abebe KZ, Steinman TI, Ye AS, Perrone RD, Braun WE, Chapman AB, Chonchol M, Nowak KL. Overweight and obesity are predictors of pain in the HALT-PKD studies. J Am Soc Nephrol. 2020;31:500

Hoover E, Baron D, Benson BA, Gitomer BY, Kleber KR, Manelli A, Mrug M, Park M, Rusconi C, Seliger SL, Perrone RD, Watnick T. Design and basic characteristics of a National patient registry in ADPKD. J Am Soc Nephrol. 2020;31:501.

Farmer-Bailey H, Cadnapaphornchai MA, You Z, George D, Wang W, Jovanovich A, Soranno D, Gitomer BY, Chonchol M, Nowak KL. Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2020;31:503

Gitomer B, Pereira R, Salusky IB, Stoneback JW, Isakova T, Cai X, Dalrymple LS, Ofsthun N, You Z, Malluche HH, Maddux F, George D, Torres V, Chapman A, Steinman TI, Wolf M, Chonchol M. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2020 Sep 11. [Epub ahead of print] PubMed PMID: 32926884

Griffin BR, You Z, Noureddine L, Gitomer B, Perrenoud L, Wang W, Chonchol M, Jalal D. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results. Am J Nephrol. 2020;51(6):473-479. PubMed PMID: 32541154

Baliga MM, Klawitter J, Christians U, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Sci Rep. 2021 Mar 23;11(1):6629. PubMed PMID: 33758231

Pereira RC, Gitomer BY, Chonchol M, Harris PC, Noche KJ, Salusky IB, Albrecht LV. Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD. JBMR Plus. 2021 Apr;5(4):e10464. PubMed PMID: 33869988

Nowak KL, Farmer-Bailey H, Cadnapaphornchai MA, You Z, George D, Wang W, Jovanovich A, Soranno DE, Gitomer B, Chonchol M. Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants. Contemp Clin Trials Commun. 2020 Sep;19:100635. PubMed PMID: 33294724

Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915. PubMed PMID: 34117082

Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2021 Aug 12. [Epub ahead of print] PubMed PMID: 34391872

Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials. Curr Hypertens Rev. 2020 Aug 17. [Epub ahead of print] PubMed PMID: 32807060

Hopp K, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui FF, Torres VE, Harris PC. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 Feb;97(2):370-382. PubMed PMID: 31874800

Pereira RC, Gitomer BY, Harris PC, Salusky IB, Albrecht LV. Primary cilia defects reflect specific bone cell activity in human ADPKD osteoblasts. J Am Soc Nephrol. 2020; 31:495

Nowak KL, Murray K, You Z, Gitomer B, Brosnahan G, Abebe KZ, Braun W, Chapman A, Harris PC, Miskulin D, Perrone R, Torres V, Steinman T, Yu A, Chonchol M. Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Med. 2021 Jul-Aug;3(4):536-545.e1. PubMed PMID: 34401721

Gitomer B, Pereira R, Salusky IB, Stoneback JW, Isakova T, Cai X, Dalrymple LS, Ofsthun N, You Z, Malluche HH, Maddux F, George D, Torres V, Chapman A, Steinman TI, Wolf M, Chonchol M. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2021 Apr;99(4):977-985. PubMed PMID: 32926884

Nguyen D, Kleczko EK, Dwivedi N, Gitomer BY, Chonchol M, Nemenoff R, Klawitter J, Hopp K. Dysregulated tryptophan metabolism promotes polycystic kidney disease progression. J Am Soc Nephrol. 2021 32:392

Nowak KL, Catenacci V, Kline TL, Wang W, You Z, Bing K, Poudyal B, Steele C, Chonchol M, Gitomer BY. Weight loss to slow cyst growth in autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol 2021 32:404

Steele C, You Z, Farmer-Bailey H, Gitomer BY, Chonchol M, Nowak KL. Overweight and obesity predict kidney growth in children and young adults with ADPKD. J Am Soc Nephrol 2021 32:404

Steele C, Klawitter J, Wang W, You Z, Catenacci V, Streumph T, George D, Gitomer BY, Brosnahan GM, Chonchol M, Nowak KL. Metabolomic changes over 1 year following drug or lifestyle interventions in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2021 32:405

Hoover R, Benson BA, Dahl NK, Gitomer BY, Manelli A, Mrug M, Park M, Rusconi C, Seliger SL, Perrone RD, Watnick TJ. Two years in: The development of basic characreristics of a national patient-powered registry in ADPKD. J Am Soc Nephrol 32:405

Nowak KL, Farmer-Bailey H, Wang W, You Z, Steele C, Cadnapaphornchai MA, Klawitter J, Patel N, George D, Jovanovich A, Soranno D, Gitomer BY, Chonchol M. Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol 2021 32:406

Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2022 Nov 24. [Epub ahead of print] PubMed PMID: 36422996

Hoover E, Perrone RD, Rusconi C, Benson B, Dahl NK, Gitomer B, Manelli A, Mrug M, Park M, Seliger SL, Phadnis MA, Thewarapperuma N, Watnick TJ. Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD. Kidney360. 2022 Aug 25;3(8):1350-1358. PubMed PMID: 36176661

Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Kynurenines in polycystic kidney disease. J Nephrol. 2022 Jul 22. [Epub ahead of print] PubMed PMID: 35867237

Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J. Endocannabinoid System in Polycystic Kidney Disease. Am J Nephrol. 2022;53(4):264-272. PubMed PMID: 35263737

Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, Nguyen DT, Bing K, Poudyal B, Johnson GC, Jackman MR, Miller M, Steele CN, Serkova NJ, MacLean PS, Nemenoff RA, Gitomer B, Chonchol M, Nowak KL. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022 Jan 21;25(1):103697. PubMed PMID: 35059607

Hopp K, Kleczko EK, Gitomer BY, Chonchol M, Klawitter J, Christians U, Klawitter J. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F258-F267. PubMed PMID: 35037466

Steele C, You Z, Gitomer BY, Brosnahan GM, Abebe KZ, Braun WE, Chapman AB, Harris PC, Perrone RD, Steinman TI, Torres VE, Yu ASL, Chonchol M, Nowak KL. PKD1 Compared With PK D2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney Int Rep. 2022 Jan;7(1):117-120. PubMed PMID: 35005320

Yang X, Wang W, Gitomer B, Cadnapaphornchai MA, Xing F, Chonchol M. Imaging Biomarkers in Young Patients With ADPKD. Kidney Int Rep. 2023 Oct;8(10):2153-2155. PubMed PMID: 37850021

Kleczko EK, Nguyen DT, Marsh KH, Bauer CD, Li AS, Monaghan MT, Berger MD, Furgeson SB, Gitomer BY, Chonchol MB, Clambey ET, Zimmerman KA, Nemenoff RA, Hopp K. Immune checkpoint activity regulates polycystic kidney disease progression. JCI Insight. 2023 Jun 22;8(12). PubMed PMID: 37345660

Steele CN, Oh ES, Wang W, Farmer-Bailey H, Gitomer BY, Chonchol M, Nowak KL. Cerebrovascular Pulsatility Index Is Reduced in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2023;54(5-6):165-174. PubMed PMID: 37231790

Perrone RD, Oberdhan D, Ouyang J, Bichet DG, Budde K, Chapman AB, Gitomer BY, Horie S, Ong ACM, Torres VE, Turner AN, Krasa H. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney Int Rep. 2023 May;8(5):989-1001. PubMed PMID: 37180499

Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2023 Jan 10;8(1). PubMed PMID: 36422996

Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Kynurenines in polycystic kidney disease. J Nephrol. 2023 Jan;36(1):83-91. PubMed PMID: 35867237

Nowak KL, Farmer-Bailey H, Wang W, You Z, Steele C, Cadnapaphornchai MA, Klawitter J, Patel N, George D, Jovanovich A, Soranno DE, Gitomer B, Chonchol M. Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2022 Feb;17(2):240-250. PubMed PMID: 34907021

Monaghan M-LT, Nguyen D, Berger MD, D'Alessandro A, Cendali FI, Gitomer BY, Chonchol M, Hopp K. Obesity and PKD: Mechanistic studies using the Pkd1RC/RC model. J Am Soc Nephrol. 2023 Nov; S:204.

Steele C, Coleman ER, George D, Farmer-Bailey H, Ramanathan S, Gregory A, Wang W, Gitomer BY, Chonchol M, Thomas E, Kline TL, Nowak KL. Time-restricted feeding ans autosomal dominant polycystic kidney disease: A pilot randomized clinical trial. J Am Soc Nephrol. 2023 Nov; S:206.

Nowak KL, You Z, Steele C, Gitomer BY, Chonchol M, Klawitter J. Kynurenines and change in body mass index in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2023 Nov; S:206.

Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2022 Apr;79(4):518-526. PubMed PMID: 34391872

Gitomer B, You Z, Brosnahan G, Wang W, Hopp K, Nowak KL, Jovanovich A, Chapman A, Perrone R, Torres V, Tu A, Chonchol M. Antibiotic use and kidney stone disease in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159.

Gitomer B, Yu Z, Brosnahan G, Wang W, Hopp K, Nowak KL, Chapman A, Perrone R, Torres V, Yu A, Chonchol M. Systemic inflamation and kidney stone disease in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159.

Gitomer BY, Wang W, George D, Nowak KL, Britz M, Klawitter J, Jovanovich A, You Z, Farmer B, Chonchol M. Baseline characteristics of participants in statin therapy in patients with early-stage ADPKD clinical trial.J Am Soc Nephrol. 2023 Nov; S:209.

Wang W, You Z, Steele C, Gitomer BY, Chonchol M, Nowak KL. Changes in tubular biomarkers with dietary intevention and metformin in patients with autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2023 Nov; S:212.

Zheng B, Gitomer BY, Nowak KL, You Z, Chonchol M. Pregnancy and its association with total kidney volume in nulliparous women with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2023 Nov; S:214.

Gitomer B, You Z, Brosnahan G, Wang W, Hopp K, Nowak KL, Chapman A, Perrone R, Torres V, Yu A, Chonchol M. Urinary clusterin associates with height corrected total kidney volume in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159.

Dwivedi N, Gitomer BY, Edelstein CL, Chonchol M, Hopp K, Brunt VE. Vascular dysfunction in the C57Bl/6J;Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease mimics human disease. J Am Soc Nephrol. 2023 Nov; S:508.

Steele CN, Oh ES, Streumph T, Farmer-Bailey H, Gitomer B, Chonchol M, Nowak KL. Cerebrovascular function in early-state autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2022 33(Suppl.2);S155-156.

Steele CN, Coleman E, Streumph T, George D, Winslow C, Gitomer B, Chonchol M. Altitude, resting metabolic rate, and autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2022 33(Suppl.2);S156.

Klawitter J, Smith PH, Chonchol M, Gitomer BY, Klawitter J. Microbiome-related changes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159-160.

Hoover E, Benson B, Dahl N, Gitomer B, Holliday V, Kleber K, Park M, Perrone R, Phadnis M, Rusconi C, Seliger S, Thewarapperuma N, Oberdhan B. Pain in ADPKD: Results from a National patient powered registry. Am J Kidney Dis. 2022 Apr;79 (4) Suppl 2: S32.

Research Professor, Medicine-Renal Med Diseases/Hypertension

Department

Publications

Practice Locations

Specialty Information

School of Medicine

CU Anschutz

Fitzsimons Building